In a report released yesterday, Faisal Khurshid from Leerink Partners reiterated a Buy rating on Kymera Therapeutics (KYMR – Research ...
Leerink Partners analyst Jonathan Chang maintained a Buy rating on Molecular Partners (MOLN – Research Report) on October 22. The ...
Fintel reports that on October 24, 2024, Leerink Partners initiated coverage of Tenax Therapeutics (NasdaqCM:TENX) with a ...
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...
Leerink Partners' affiliate, MEDACorp, announced today the launch of a new division, the Center for Pharmacoeconomics (CPE), which will be dedicated to advancing the understanding of the societal ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company ...
Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
On Thursday, Progyny Inc (PGNY) stock saw a decline, ending the day at $15.55 which represents a decrease of $-0.31 or -1.95% from the prior close of $15.86. The stock opened at $15.84 and touched a ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 12.84% ...
Leerink Partners maintained their Outperform rating on Roivant Sciences (NASDAQ:ROIV) with a steady price target of $17.00. The firm's analyst highlighted Roivant's executive incentive compensation ...
Leerink Partners maintained their Outperform rating on Roivant Sciences (NASDAQ:ROIV) with a steady price target of $17.00. The firm's analyst highlighted Roivant's executive incentive ...
On Monday, Leerink Partners adjusted their outlook on Elevance Health Inc (NYSE:ELV) shares, reducing the price target to $515 from the previous $620, while retaining an Outperform rating on the ...